Charlotte's Web Holdings, Inc. · TSX:CWEB
Charlotte's Web — Investor Presentation (2026)
27 slides from Charlotte's Web's investor presentation, Apr 27, 2026
Slide 1: Charlotte's Web was started as a mission
CHARLOTTE’ S WEB WAS NOT STARTED AS A COMPANY IT WAS STARTED AS A MISSION, AND LAUNCHED THE CBD CATEGORY 2026 TSX: CWEB.TO | OTC: CWBHF Charlotte’s Web, Inc. 1
Slide 2: Disclaimers
DISCLAIMERS Forward-Looking Information Certain statements contained in this presentation constitute forward-looking statements and forward-looking information (collectively, “forward-looking statements”). Such forward-looking statements relate to possible events, conditions or financial performance
Slide 3: The Charlotte's Web Legacy
The Charlotte’s Web Legacy In 2013, the founders of Charlotte’s Web developed a groundbreaking, proprietary hemp extract to help Charlotte Figi, a little girl suffering from over 300 seizures a week. Her story ignited a global movement, reshaped laws and public perceptions, and inspired trailblazing
Slide 4: Our Brand in the Media
Our Brand in the Media More than any other CBD brand, from the Today Show to Fox News to CNN to front pages of The New York Times — our story and products have been shared across the biggest names in broadcast, digital, print, and emerging media. With award-winning storytelling that’s reached tens o
Slide 5: Key Investment Highlights
Key Investment Highlights ✓ #1 CBD Brand: Charlotte's Web is the largest U.S. CBD company and the #1 CBD brand. ✓ Recapitalized for Growth: BAT debenture conversion plus US$10 million private placement (subject to shareholder approval at the May 28, 2026 AGM) eliminates the Company's largest balance
Slide 6: Wellbeing is Our Business
Wellbeing is Our Business The gold standard for CBD, Charlotte’s Web is a publicly traded company rooted in America’s heartland with a vertically integrated supply chain. Charlotte’s Web is known for: • Proprietary hemp genetics grown in American soil, cultivated by American family farmers in Arizon
Slide 7: General Wellness Portfolio
General Wellness Portfolio Tinctures, Gummies, Soft Gels, Topicals Pet Chews & Tinctures Charlotte’s Web, Inc. 7 © 2026 Charlotte’s Web, Inc. All Rights Reserved.
Slide 8: Clinical Studies – Safety and Regulatory
Clinical Studies – Safety and Regulatory Clinical Studies: Safety and Regulatory • Self-affirmed GRAS • Full Toxicology Studies • FDA NDIN • Pharmacokinetic Study • Efficacy Studies • Pre-Clinical Disease States • UK/EU Novel Foods © 2026 Charlotte’s Web, Inc. All Rights Reserved.
Slide 9: Operational Excellence
Operational Excellence • 135,000 sq. ft. facility in Louisville, Colorado consolidates Production, Research & Development, Quality Control, and Distribution • In-house utilities: lab gases, steam, chilled water, compressed air, and centralized boiler systems • Advanced capabilities: multi-method CBD
Slide 10: Best-in-Class Quality
Best-in-Class Quality Charlotte’s Web’s Research & Development and Quality teams are the cornerstone of its industry leadership, setting it apart from other CBD producers through scientific rigor, innovation, and product integrity. Whole Plant Science Quality Control from Seed to Science-Driven Cert
Slide 11: CW Innovation
CW Innovation Medical and General Wellness Innovation Addressing a Variety of Need States
Slide 12: New Product Innovation Released in 2025
New Product Innovation Released in 2025 Focus and Attention CBG Quiet Sleep All Brightside by Charlotte's Web products are fast-acting, with onset between 7-10 minutes © 2026 Charlotte’s Web, Inc. All Rights Reserved.
Slide 13: Charlotte's Web Innovative Medical Line
Charlotte's Web Innovative Medical Line Addressing Sleep, Pain, Anxiety and Overall Wellness © 2026 Charlotte’s Web, Inc. All Rights Reserved.
Slide 14: 13 Years in the Making… Prepared for the Future
13 Years in the Making… Prepared for the Future • Full ingredient traceability and transparency 1 . Ve r t i ca l • Hemp grown on 100% North American family farms Integration • World-class plant breeding program • 8 patents on hemp cultivars • FDA registered cGMP facility 2. Science & • NASC certifi
Slide 15: Federal Regulatory Movements
Federal Regulatory Movements A widening pathway for compliant, quality-led hemp-derived CBD Appropriations Act language restricting hemp-derived THC content (effective Nov 2026) has accelerated bipartisan momentum toward a durable federal framework, with multiple legislative and regulatory pathways
Slide 16: Medicare – the CBD for Seniors Opportunity
Medicare – the CBD for Seniors Opportunity
Slide 17: December 18, 2025 Executive Order Directs Federal Framework
December 18, 2025 A Presidential Executive Order directed federal agencies to establish a regulatory framework for hemp-derived CBD, marking the most significant Executive Order federal action on the category to date. Directs Federal In parallel, the Centers for Medicare & Medicaid Framework for Hem
Slide 18: What is a Medicare ACO?
What is a Medicare ACO? • A group of hospitals, ACO physician practices, and care 103 coordinators collaborating to improve patient outcomes ACO's and reduce healthcare costs 160K • Approximately 160K physicians participate in the Physicians 103 ACO's throughout the nation 2.5M Patients • Approximat
Slide 19: DeFloria – the Autism Biotech Opportunity
DeFloria – the Autism Biotech Opportunity
Slide 20: DeFloria to enter Phase 2 FDA Clinical Trial
PRESS RELEASE Charlotte’s Web Announces DeFloria to enter Phase 2 FDA Clinical Trial for Autism Spectrum Disorder Treatment LOUISVILLE, Colo. - Feb 24, 2025 - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a market leader in hemp extract wellness prod
Slide 21: Formation of DeFloria for FDA IND
Formation of “DeFloria” for FDA IND PARTNERING TO PURSUE BOTANICAL DRUG THROUGH FDA DeFloria, Inc. DEFLORIA PARTNER CONTRIBUTIONS: CHARLOTTE'S WEB Licensing IP, clinical data, proprietary hemp genetics, and manufacturing expertise. Approximately one-third ownership of DeFloria. AJNA BioSciences Bota
Slide 22: Botanical Drug Pathway
Botanical Drug Pathway BOTANICAL DRUG DEVELOPMENT • Indication: Behavioral Symptoms associated with Autism Spectrum Disorder • Whole plant full-spectrum botanical vs single active compound • Decade of observational studies, foundational safety and toxicity data UNLOCKING IP AND ASSET VALUE • Unique
Slide 23: Charlotte's Web #1 in a Fragmented Market
Charlotte’s Web #1 in SUBSTANTIAL a Fragmented Market MARKET UPSIDE Pharmaceutical Top 20 CBD CBD Companies Charlotte’s Web (~16%) (~17%) CW holds 6% of share in segments it participates in (3% of total market) $2bn market share available ~1500 CBD Enormous room for market share Companies gains thro
Slide 24: Returning to Growth
Returning to Growth Four years of revenue declines in a Four consecutive quarters of sequential challenged CBD sector required growth delivered the first annual revenue new leadership and turnaround increase since 2021, validating the strategies turnaround strategy. Q4 2025 finished as the strongest
Slide 25: Clean balance sheet anchored by long-term strategic partner
Clean balance sheet anchored by long-term strategic partner Q1 2026 Recapitalization With British American Tobacco TRANSACTION STRUCTURE Amendment and conversion of BAT's outstanding convertible debenture, including accrued interest, with concurrent additional equity investment of approximately $10
Slide 26: Positioned to deliver long term shareholder value
POSITIONED To deliver long #1 in a $2B consumer market Regulations can shake out marketplace term shareholder Differentiated full and broad-spectrum product portfolio value New innovations: cannabinoid isolates and functional mushroom wellness blends Long-term upside with DeFloria Botanical Drug opp
Slide 27: Charlotte's Web Holdings, Inc.
TSX:CWEB | OTC:CWBHF Charlotte’s Web Holdings, Inc. 700 Tech Court Louisville, Colorado USA www.charlottesweb.com Cory Pala Director of Investor Relations (720) 484-8930 IR@CharlottesWeb.com Charlotte’s Web, Inc. 27 © 2026 Charlotte’s Web, Inc. All Rights Reserved.
Charlotte's Web Holdings — Investor Presentation (2026) on 6ix